Last reviewed · How we verify

NCT03965442

Effects of Intraoperative Esmolol on Post-mastectomy Pain Syndrome

Status unknown Last updated 29 May 2019
What this trial tests

trial testing Control in Post-mastectomy Pain Syndrome in 66 participants. Status unknown.

Timeline
1 January 2019
Primary endpoint
31 July 2019
31 July 2019

Quick facts

Lead sponsorHospital de Base
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment66
Start date1 January 2019
Primary completion31 July 2019
Estimated completion31 July 2019
Sites1 location across Brazil

Drugs / interventions tested

Conditions studied

Sponsor

Hospital de Base

Who can join

Adults 18 to 65, female only, with Post-mastectomy Pain Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Chronic postoperative pain is an entity that is usually neglected by anesthetists, but several studies show that the choice of anesthetic technique may interfere with this prevalence. Esmolol is a selective beta-blocker of ultra fast duration that has been studied as a perioperative venous adjuvant with antihyperalgesic and opioid sparing action. The investigators ventured the possibility of this anti-hyperalgesic effect attenuating the chronic pain syndrome post-mastectomy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Control

Trials testing the same drug.

Other recruiting trials for Post-mastectomy Pain Syndrome

Currently open trials in the same condition.

Other Hospital de Base trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03965442.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing